<DOC>
	<DOCNO>NCT01948726</DOCNO>
	<brief_summary>Hypofractionation simultaneous integrate boost investigate trial appear safe feasible less lung toxicity small study . Investigators initiate multicenter phase II prospective trial analyse acute toxicity hypofractionation simultaneous integrate boost patient early breast cancer hypothesis ratio patient acute radiogenic toxicity Grad II accord NCI-CTCAE amount maximum 20 % .</brief_summary>
	<brief_title>Hypofractionation With Simultaneous Integrated Boost Early Breast Cancer</brief_title>
	<detailed_description>Hypofractionated radiotherapy breast 16 × 2.50 Gy simultaneous integrate boost tumor bed ( total dose within boost volume 16 × 3.00 Gy ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histopathologically confirm breast cancer operate breast conserve surgery clear margin Indication adjuvant radiotherapy include boost radiotherapy Clearly identify primary tumor region preferably radiopaque clip Primary wind heal breast conserve therapy without sign infection Pre and/or postoperative chemotherapy endocrine therapy permit indicated Written inform consent Patients operate mastectomy No indication boost radiation Resection margin positive disease insufficient identification boost volume Indication radiotherapy regional lymph node History prior breast thoracic radiotherapy Extended postoperative seroma begin radiotherapy Psychiatric disorder psychological disability think adversely affect treatment compliance Pregnant lactating patient woman child bear potential , lack effective contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Hypofractionation</keyword>
	<keyword>Simultaneous integrate boost</keyword>
	<keyword>Toxicity</keyword>
</DOC>